Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy

Author： Judge Daniel P.   Kass David A.   Thompson W. Reid   Wagner Kathryn R.  

Publisher： Adis International

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.11, Iss.5, 2011-10, pp. : 287-294

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging drugs for Duchenne muscular dystrophy

By Malik Vinod   Rodino-Klapac Louise R.   Mendell Jerry R  

Expert Opinion on Emerging Drugs, Vol. 17, Iss. 2, 2012-06 ,pp. : 261-277

Informa Healthcare

Access to resources Recommend Favorite

Molecular pathophysiology and targeted therapeutics for muscular dystrophy

By Hoffman E.P.   Dressman D.  

Trends in Pharmacological Sciences, Vol. 22, Iss. 9, 2001-09 ,pp. : 465-470

Elsevier

Access to resources Recommend Favorite

Duchenne muscular dystrophy drug discovery – the application of utrophin promoter activation screening

By Moorwood Catherine   Khurana Tejvir S  

Expert Opinion on Drug Discovery, Vol. 8, Iss. 5, 2013-06 ,pp. : 569-581

Informa Healthcare

Access to resources Recommend Favorite

Deflazacort helps to maintain both muscle and pulmonary function in Duchenne muscular dystrophy

By  

Inpharma, Vol. 1, Iss. 1275, 2001-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Personalised Genetic Intervention for Duchenne Muscular Dystrophy: Antisense Oligomers and Exon Skipping

By  

Current Molecular Pharmacology, Vol. 2, Iss. 1, 2009-01 ,pp. : 110-121

Bentham Science Publishers

Access to resources Recommend Favorite